Insight Molecular Diagnostics (IMDX) Return on Sales (2020 - 2025)
Historic Return on Sales for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 42.49%.
- Insight Molecular Diagnostics' Return on Sales rose 750300.0% to 42.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.93%, marking a year-over-year increase of 245400.0%. This contributed to the annual value of 32.45% for FY2024, which is 305000.0% down from last year.
- According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Return on Sales is 42.49%, which was up 750300.0% from 19.0% recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' Return on Sales registered a high of 1.95% during Q4 2023, and its lowest value of 120.3% during Q4 2022.
- Its 5-year average for Return on Sales is 35.81%, with a median of 22.63% in 2024.
- Per our database at Business Quant, Insight Molecular Diagnostics' Return on Sales skyrocketed by 6166400bps in 2021 and then plummeted by -1103500bps in 2022.
- Quarter analysis of 5 years shows Insight Molecular Diagnostics' Return on Sales stood at 9.94% in 2021, then crashed by -1110bps to 120.3% in 2022, then skyrocketed by 98bps to 1.95% in 2023, then crashed by -1062bps to 22.63% in 2024, then tumbled by -88bps to 42.49% in 2025.
- Its Return on Sales was 42.49% in Q3 2025, compared to 19.0% in Q2 2025 and 3.18% in Q1 2025.